DoxorubicinAntibiotics, AntineoplasticAntineoplastic AgentsDrug Resistance, NeoplasmAntineoplastic Combined Chemotherapy ProtocolsCell Line, TumorVincristineCyclophosphamideCisplatinApoptosisRazoxanePaclitaxelDrug Resistance, MultipleP-GlycoproteinDrug SynergismEtoposideTumor Cells, CulturedCell SurvivalBreast NeoplasmsDrug CarriersDrug Screening Assays, AntitumorAntineoplastic Agents, PhytogenicDose-Response Relationship, DrugVinblastineFluorouracilDaunorubicinLiposomesNeoplasmsDrug Delivery SystemsMice, NudeXenograft Model Antitumor AssaysDrug ResistancePrednisoneCombined Modality TherapyDrug Administration ScheduleBleomycinMethotrexateAntineoplastic Agents, AlkylatingPolyethylene GlycolsCardiotoxinsTreatment OutcomeMitoxantroneCell ProliferationInhibitory Concentration 50TaxoidsDacarbazineLeukemia P388AnthracyclinesLung NeoplasmsIfosfamideTumor Suppressor Protein p53Neoplasm TransplantationAntimetabolites, AntineoplasticDNA DamageMitomycinOsteosarcomaOvarian NeoplasmsDeoxycytidineProto-Oncogene Proteins c-bcl-2ProdrugsSarcomaCell CycleGene Expression Regulation, NeoplasticTime FactorsMultidrug Resistance-Associated ProteinsHydroxyethylrutosideDisease-Free SurvivalSurvival AnalysisCaspasesTransplantation, HeterologousDNA Topoisomerases, Type IICarmustineCamptothecinVerapamilGenes, MDRBlotting, WesternRNA, Small InterferingNanocapsulesBone NeoplasmsColonic NeoplasmsInfusions, IntravenousTopoisomerase II InhibitorsCaspase 3Chemotherapy, AdjuvantMechlorethamineCell DeathCell DivisionLiver NeoplasmsMice, SCIDCytarabineFlow CytometryCardiomyopathiesSurvival RateMelphalanNeoplasm ProteinsEpirubicinAdenocarcinomaNoscapineNanoparticlesHeart Diseases